JP2017141277A5 - - Google Patents

Download PDF

Info

Publication number
JP2017141277A5
JP2017141277A5 JP2017075145A JP2017075145A JP2017141277A5 JP 2017141277 A5 JP2017141277 A5 JP 2017141277A5 JP 2017075145 A JP2017075145 A JP 2017075145A JP 2017075145 A JP2017075145 A JP 2017075145A JP 2017141277 A5 JP2017141277 A5 JP 2017141277A5
Authority
JP
Japan
Prior art keywords
administration
pharmaceutical composition
pain
formulation
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017075145A
Other languages
English (en)
Japanese (ja)
Other versions
JP6423036B2 (ja
JP2017141277A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017141277A publication Critical patent/JP2017141277A/ja
Publication of JP2017141277A5 publication Critical patent/JP2017141277A5/ja
Application granted granted Critical
Publication of JP6423036B2 publication Critical patent/JP6423036B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017075145A 2010-06-15 2017-04-05 痛み治療用の医薬配合物 Expired - Fee Related JP6423036B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10006202.5 2010-06-15
EP10006202 2010-06-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015151003A Division JP6197007B2 (ja) 2010-06-15 2015-07-30 痛み治療用の医薬配合物

Publications (3)

Publication Number Publication Date
JP2017141277A JP2017141277A (ja) 2017-08-17
JP2017141277A5 true JP2017141277A5 (US06780888-20040824-C00057.png) 2017-10-05
JP6423036B2 JP6423036B2 (ja) 2018-11-14

Family

ID=42395008

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013514579A Expired - Fee Related JP6133772B2 (ja) 2010-06-15 2011-06-14 痛み治療用の医薬配合物
JP2015151003A Expired - Fee Related JP6197007B2 (ja) 2010-06-15 2015-07-30 痛み治療用の医薬配合物
JP2017075145A Expired - Fee Related JP6423036B2 (ja) 2010-06-15 2017-04-05 痛み治療用の医薬配合物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2013514579A Expired - Fee Related JP6133772B2 (ja) 2010-06-15 2011-06-14 痛み治療用の医薬配合物
JP2015151003A Expired - Fee Related JP6197007B2 (ja) 2010-06-15 2015-07-30 痛み治療用の医薬配合物

Country Status (29)

Country Link
US (3) US8846765B2 (US06780888-20040824-C00057.png)
EP (2) EP2992877A1 (US06780888-20040824-C00057.png)
JP (3) JP6133772B2 (US06780888-20040824-C00057.png)
KR (1) KR101831616B1 (US06780888-20040824-C00057.png)
CN (1) CN103108631B (US06780888-20040824-C00057.png)
AR (1) AR081931A1 (US06780888-20040824-C00057.png)
AU (2) AU2011267474B2 (US06780888-20040824-C00057.png)
BR (1) BR112012031836A2 (US06780888-20040824-C00057.png)
CA (1) CA2796774C (US06780888-20040824-C00057.png)
CL (1) CL2012002551A1 (US06780888-20040824-C00057.png)
CO (1) CO6602157A2 (US06780888-20040824-C00057.png)
CY (1) CY1117118T1 (US06780888-20040824-C00057.png)
DK (1) DK2582366T3 (US06780888-20040824-C00057.png)
EC (2) ECSP12012217A (US06780888-20040824-C00057.png)
ES (1) ES2560676T3 (US06780888-20040824-C00057.png)
HK (2) HK1184370A1 (US06780888-20040824-C00057.png)
HR (1) HRP20151327T1 (US06780888-20040824-C00057.png)
HU (1) HUE026619T2 (US06780888-20040824-C00057.png)
IL (1) IL221926A (US06780888-20040824-C00057.png)
MX (1) MX2012014482A (US06780888-20040824-C00057.png)
NZ (1) NZ602625A (US06780888-20040824-C00057.png)
PE (2) PE20130243A1 (US06780888-20040824-C00057.png)
PL (1) PL2582366T3 (US06780888-20040824-C00057.png)
PT (1) PT2582366E (US06780888-20040824-C00057.png)
RS (1) RS54439B1 (US06780888-20040824-C00057.png)
RU (2) RU2589692C2 (US06780888-20040824-C00057.png)
SI (1) SI2582366T1 (US06780888-20040824-C00057.png)
WO (1) WO2011157391A1 (US06780888-20040824-C00057.png)
ZA (1) ZA201208646B (US06780888-20040824-C00057.png)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011157391A1 (en) * 2010-06-15 2011-12-22 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US20130236573A1 (en) * 2012-03-12 2013-09-12 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
WO2014116739A1 (en) * 2013-01-22 2014-07-31 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses l-4-chlorokynurenine
CN105073096A (zh) 2013-03-15 2015-11-18 詹森药业有限公司 S-盐酸氯胺酮的药物组合物
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
KR20220102662A (ko) * 2014-05-06 2022-07-20 노쓰웨스턴유니버시티 Nmdar 조절 화합물의 조합물
CA2957926A1 (en) 2014-08-13 2016-02-18 Janssen Pharmaceutica Nv Method for the treatment of depression
MX2017003366A (es) 2014-09-15 2018-02-01 Janssen Pharmaceutica Nv Regimenes de dosificacion y métodos especificos para el tratamiento de la depresión con el genotipo val66met (snp rs6265).
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
CA2987909C (en) 2015-06-27 2022-04-26 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
RU2020123893A (ru) 2017-12-22 2022-01-24 Янссен Фармасьютикалз, Инк. Эскетамин для лечения депрессии
WO2019200345A1 (en) * 2018-04-12 2019-10-17 Anavex Life Sciences Corp. A2-73 crystalline polymorph compositions of matter and methods of use thereof
US20230117657A1 (en) 2019-03-05 2023-04-20 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6248789B1 (en) * 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
IL140834A0 (en) * 1998-07-16 2002-02-10 Sloan Kettering Inst Cancer Topical compositions comprising an opioid analgesic and an nmda antagonist
DE10005302A1 (de) * 2000-02-07 2002-01-17 Gruenenthal Gmbh Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
DE10163421A1 (de) * 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
JP2003201254A (ja) * 2001-12-28 2003-07-18 Hisamitsu Pharmaceut Co Inc 鎮痛剤活性増強剤の治療上有効な血中濃度を維持するための製剤
JP2003210254A (ja) * 2002-01-18 2003-07-29 Nihon Form Service Co Ltd 車椅子専用ラック
EP1545461A4 (en) * 2002-09-09 2011-06-22 Endo Pharmaceuticals Inc COMBINED ANALGESIC COMPOSITION WITH IMMEDIATE AND PROLONGED RELEASE
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
WO2007087452A2 (en) * 2006-01-27 2007-08-02 Theraquest Biosciences, Llc Abuse resistant and extended release formulations and method of use thereof
PT2012764E (pt) 2006-04-28 2011-02-02 Gruenenthal Gmbh Combinação farmacêutica que compreende 3-(3-dimetilamino-1- etil-2-metilpropil)fenol e paracetamol
ES2358763T3 (es) 2006-04-28 2011-05-13 Grünenthal GmbH Combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y un nsaid.
US20070254960A1 (en) 2006-04-28 2007-11-01 Gruenenthal Gmbh Pharmaceutical combination
EP1857463A1 (en) 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Peptide having neuroprotective effects
BRPI0712494A2 (pt) * 2006-06-08 2012-10-09 Sanol Arznei Schwarz Gmbh combinação terapêutica para consições médicas dolorosas
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007012165A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
LT2596784T (lt) * 2007-11-23 2017-03-27 Grünenthal GmbH Tapentadolio kompozicijos
EP2250148B1 (en) * 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
EP2249811A1 (en) 2008-01-25 2010-11-17 Grünenthal GmbH Pharmaceutical dosage form
KR101851120B1 (ko) 2008-09-05 2018-04-23 그뤼넨탈 게엠베하 3-(3-디메틸아미노-1-에틸-2-메틸-프로필)-페놀과 항간질제의 약제학적 병용물
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
WO2011157391A1 (en) * 2010-06-15 2011-12-22 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
DK2619212T3 (en) 2010-09-21 2016-03-21 Purdue Pharma Lp BUPRENORPHINANALOGER AS opioid receptor agonists and / or antagonists
CN103370058A (zh) 2010-12-22 2013-10-23 普渡制药公司 包覆的抗篡改控制释放剂型
HUE027514T2 (en) 2011-03-04 2016-10-28 Gruenenthal Gmbh Parenteral administration of tapentadol
SG11201406025UA (en) 2012-04-17 2014-11-27 Purdue Pharma Lp Systems and methods for treating an opioid-induced adverse pharmacodynamic response

Similar Documents

Publication Publication Date Title
JP2017141277A5 (US06780888-20040824-C00057.png)
HRP20190500T1 (hr) Farmaceutska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola i pregabalina ili gabapentina
JP2017530984A5 (US06780888-20040824-C00057.png)
HRP20151327T1 (hr) Farmaceutska kombinacija za lijeäśenje boli
JP2017528503A5 (US06780888-20040824-C00057.png)
JP2016534063A5 (US06780888-20040824-C00057.png)
JP2008543854A5 (US06780888-20040824-C00057.png)
JP2013534248A5 (US06780888-20040824-C00057.png)
JP2015155440A5 (US06780888-20040824-C00057.png)
JP2019507781A5 (US06780888-20040824-C00057.png)
JP2020097577A5 (US06780888-20040824-C00057.png)
JP2017523225A5 (US06780888-20040824-C00057.png)
JP2016531871A5 (US06780888-20040824-C00057.png)
JP2015518004A5 (US06780888-20040824-C00057.png)
RU2013121788A (ru) Ингибиторы репликации вич
RU2008146816A (ru) Фармацевтическая комбинация, содержащая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и парацетамол
JP2010532768A5 (US06780888-20040824-C00057.png)
JP2014500861A5 (US06780888-20040824-C00057.png)
JP2011530545A5 (US06780888-20040824-C00057.png)
JP2017517565A5 (US06780888-20040824-C00057.png)
JP2016510326A5 (US06780888-20040824-C00057.png)
RU2015149527A (ru) Производные доластатина 10 и ауристатинов
JP2019510081A5 (US06780888-20040824-C00057.png)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2017508817A5 (US06780888-20040824-C00057.png)